Search Press releases Keywords From To 1 Feb 2022 UCB Commences Tender Offer to Acquire Zogenix, Inc. Read More 28 Jan 2022 Disposals of own shares Read More 24 Jan 2022 BIMZELX[®] (bimekizumab) Approved in Japan for the Treatment of Plaque Psoriasis, Generalized Pustular Psoriasis and Psoriatic Erythroderma Read More 21 Jan 2022 Disposals of own shares Read More 21 Jan 2022 Positive Top-Line Results for BIMZELX[®]▼(bimekizumab) in Second Phase 3 Psoriatic Arthritis Study Read More 19 Jan 2022 UCB to acquire Zogenix Read More Pagination First page Previous page Previous … Page 32 Page 33 Page 34 Page 35 Current page 36 Page 37 Page 38 Page 39 Page 40 … Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
